ERENUMAB, A NEW PREVENTIVE TREATMENT FOR MIGRAINE: MECHANISM OF ACTION, SAFETY AND EFFICACY
Authors:
- Mikołaj JońcaMJMikołaj Jońca
- Natasza KurysNKNatasza Kurys
- Mikhail KazachokMKMikhail Kazachok
- Szymon ParuszewskiSPSzymon Paruszewski
- Julia KupczakJKJulia Kupczak
- Aleksandra DybcioADAleksandra Dybcio
- Katarzyna KupczykKKKatarzyna Kupczyk
- Dorota SzydłowskaDSDorota Szydłowska
- Adam KubisaAKAdam Kubisa
- Mateusz MiluskiMMMateusz Miluski
Open Access
- 25 June 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Abstract
Background: Migraine is a common, debilitating and one of the most disabling of the neurovascular disorders. The common treatment has been based on non-specific medications derived from other clinical disciplines such as beta-blockers, antiepileptics and antidepressants, which have variable efficacy and many unwanted side effects and are therefore frequently discontinued. The recent knowledge about the involvement of CGRP and its receptors in migraine pathophysiology has opened new avenues for anti-migraine treatment. Objectives: The aim of this paper is to comprehensively review the mechanism of action, clinical efficacy, safety profile, and comparative effectiveness of erenumab - the first fully human monoclonal antibody designed specifically for migraine prevention. Methods: A narrative review of the current medical literature was conducted using the PubMed database. The analysis included data from phase 2, 3 and 4 randomized controlled trials, long-term open-label extensions, and current international neurological guidelines. Results: Erenumab is a monoclonal antibody that selectively targets the canonical CGRP receptor and functions as a competitive receptor antagonist. Binding of erenumab to the CGRP receptor does not result in vasoconstriction and does not interact with the CYP450 enzyme system. Studies including STRIVE, ARISE and LIBERTY trials have demonstrated the high efficacy of erenumab in the reduction of MMD in both EM and CM patients, including those who have failed multiple prior prophylactic treatments. The HER-MES trial has further confirmed the high tolerability of erenumab and a higher retention rate compared to topiramate. The safety profile is highly favorable, with injection site reactions and constipation being the most frequently reported adverse events. Furthermore, erenumab can safely be given alongside with novel acute treatments, such as gepants and ditans. Conclusions: Erenumab holds great promise in migraine prophylaxis as it’s offering a targeted, highly effective, and well-tolerated therapeutic option. Future research should focus on its long-term efficacy in a real-world setting. One important aspect will be to explore its safety during pregnancy and in children. An interesting and potentially clinically useful aspect for non-responders will be exploring the possibility of combining it with antibodies against other neuropeptide pathways, such as those involving PACAP.Keywords
This publication has 88 references indexed in Scilit:
- Inpatient Constipation Among Migraine Patients Prescribed Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies and Standard of Care Antiepileptic Drugs: A Retrospective Cohort Study in a United States Electronic Health Record DatabasePain and Therapy, 2022
- A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy FemalesCNS Drugs, 2019
- Botulinum toxins for the prevention of migraine in adultsCochrane Database of Systematic Reviews, 2018
- Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of ActionNeurotherapeutics, 2017
- Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?Current Treatment Options in Neurology, 2017
- Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine SubjectsPharmaceutical Research, 2017
- Usefulness of nutraceuticals in migraine prophylaxisNeurological Sciences, 2017
- Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to DateClinical Pharmacology in Drug Development, 2017
- Diclofenac with or without an antiemetic for acute migraine headaches in adults2012
- Non-pharmacological management of migraine during pregnancyNeurological Sciences, 2010